Funding · Biotech
Shennon Biotechnologies raises $12m for oncology programs
Its early pipeline includes programs for small-cell lung, ovarian and liver cancers.
Foundation Capital, Atypical Ventures and Saras Capital are also named investors.
Shennon plans to continue development of its integrated technology platform and advance its oncology pipeline.
The company has three emerging T-cell engager programs for small-cell lung, ovarian and liver cancers. The platform and candidates remain in discovery and preclinical development.
Use of funds
Continue development of integrated technology platform
Advance oncology pipeline
Funding history
Funding · This round$12M